Kelly, Daniel P. 2 R01 DK045416-13 PLAN FOR MODEL ORGANISM AND REAGENT SHARING Our plan to share the mouse models described in this application adheres to the NIH Grant Policy on Sharing of Unique Research Resources, including the Sharing of Biomedical Research Resources Principles and Guidelines for Recipients of NIH Grants and Contracts issued in December 1999 (http://ott.od.nih.gov/NewPages/RTguide_final.html). All of the mouse models generated by this project will be distributed freely either before or immediately after publication. Over the past 5 years, our laboratory has demonstrated its commitment to sharing by providing several mouse models to other investigators, including the MHC-PPAR mice (Finck et al., JCI 2002;109:121-130), the tet-on PGC-1 mice (Russell et al., Circ. Res. 2004; 94:525-533) and, more recently, the PGC-1-deficient mice (Leone et al., PLoS Biol. 2005; 3:1-16). Following the characterization and peer-reviewed publication of the transgenic mouse strain generated, mice will be freely distributed to investigators at academic institutions wanting mice for noncommercial research. We will fill requests for the models in a timely fashion. In addition, we will provide relevant protocols and published genetic and phenotypic data upon request. Material transfers will be made with no more restrictive terms than in the Simple Letter Agreement (SLA) or the Uniform Biological Materials Transfer Agreement (UBMTA). The recipient investigators will be asked to provide written assurance and evidence that the animals will be used solely in accord with their local Association for Assessment and Accreditation of Laboratory Animal Care International (IACUC) review and that animals will not be used for commercial purposes. Should any intellectual property arise which requires a patent, we will ensure that the technology (materials and data) remains widely available to the research community in accordance with the NIH Principles and Guidelines document. Requests for mice from for-profit corporations to use the mice commercially will be negotiated by our institution’s technology transfer office. All licensing shall be subject to distribution pursuant to my institution’s policies and procedures on royalty income. The technology transfer office will report any invention disclosure submitted to them to the appropriate Federal Agency. In addition, other investigators will have access to phenotypic characterizations of our genetically engineered mouse lines through the NIH supported Mouse Genome Database (MGD, http://www.informatics.jax.org). All submissions are edited for nomenclature and content by MGD before approval. To facilitate sharing and distribution of the transgenic/knockout mice and associated resources developed under this grant, mice will be maintained in a specific pathogen-free facility. This facility will maintain the mice free of the following micro-organisms and pathogens: mouse hepatitis virus, sendai virus, mycoplasma, GDVII virus, REO3 virus, ectromelia virus, pneumonia virus of mice, rotavirus, lymphocytic choriomenigitis virus, minute virus of mice, K virus, polyoma virus, cytomegalovirus, mouse adenovirus, and mouse parvovirus. Should the transgenic/knockout mice become infected with any of these micro-organisms, the mice will be rederived through embryo transfer.
2
Kelly, Daniel P. 2 R01 DK045416-13 “Other Research Resources” generated with funds from this grant will include DNA constructs, etc. These resources, as available, would also be freely distributed upon request to qualified academic investigators for noncommercial research. Again, my institution and I will adhere to the NIH Grants Policy on Sharing of Unique Research Resource, including the “Sharing of Biomedical Research Resources: Principles and Guidelines for Recipients of NIH Grants and Contracts” issued in December 1999 (http://ott.od.nih.gov/NewPages/Rtguide_final.html). Specifically, material transfers would be made with no more restrictive terms than in the Simple Letter Agreement or the UBMTA and without reach through requirements. Should any intellectual property arise which requires a patent, we would ensure that the technology remains widely available to the research community in accordance with the NIH Principles and Guidelines document.
3